CompletedEarly Phase 1

Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery

United States1 participantsStarted 2014-01-21

Plain-language summary

This pilot trial studies propranolol hydrochloride in treating patients with locally recurrent or metastatic solid tumors that cannot be removed by surgery. Propranolol hydrochloride may slow the growth of tumor cells by blocking the use of hormones by the tumor cells.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Pathologically (histologically or cytologically) proven diagnosis of HCC.
. At least one solid liver lesion or vascular tumor thrombosis (involving portal vein, IVC and/or hepatic vein) \> 1 cm with arterial enhancement and delayed washout on multiphasic computerized tomography (CT) or magnetic resonance imaging (MRI) in the setting of cirrhosis or chronic hepatitis B or C without cirrhosis.
. For patients whose CURRENT disease is vascular only: Enhancing vascular thrombosis (involving portal vein, IVC and/or hepatic vein) demonstrating early arterial enhancement and delayed washout on multi-phasic CT or MRI, in a patient with known HCC (diagnosed according to criteria in (a) or (b).

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Incidence of toxicity graded according to Common Terminology Criteria for Adverse Events (CTCAE) V. 4.0

Timeframe: Up to 4 months

Change in vascular endothelial growth factor (VEGF)

Timeframe: Baseline to 4 months

Effect of beta-adrenergic blockade on the tumor microenvironment

Timeframe: Up to 4 months

Effect of beta-adrenergic blockade on the host immune system

Timeframe: Up to 4 months

Trial details

NCT IDNCT02013492

SponsorWilliam Carson

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-06-12

View on ClinicalTrials.gov More Male Breast Cancer trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Pathologically (histologically or cytologically) proven diagnosis of HCC.
. At least one solid liver lesion or vascular tumor thrombosis (involving portal vein, IVC and/or hepatic vein) \> 1 cm with arterial enhancement and delayed washout on multiphasic computerized tomography (CT) or magnetic resonance imaging (MRI) in the setting of cirrhosis or chronic hepatitis B or C without cirrhosis.
. For patients whose CURRENT disease is vascular only: Enhancing vascular thrombosis (involving portal vein, IVC and/or hepatic vein) demonstrating early arterial enhancement and delayed washout on multi-phasic CT or MRI, in a patient with known HCC (diagnosed according to criteria in (a) or (b).

What they're measuring

Incidence of toxicity graded according to Common Terminology Criteria for Adverse Events (CTCAE) V. 4.0

Timeframe: Up to 4 months

Change in vascular endothelial growth factor (VEGF)

Timeframe: Baseline to 4 months

Effect of beta-adrenergic blockade on the tumor microenvironment

Timeframe: Up to 4 months

Effect of beta-adrenergic blockade on the host immune system

Timeframe: Up to 4 months